Cargando…
Pediatric cancer gone viral. Part I: strategies for utilizing oncolytic herpes simplex virus-1 in children
Progress for improving outcomes in pediatric patients with solid tumors remains slow. In addition, currently available therapies are fraught with numerous side effects, often causing significant life-long morbidity for long-term survivors. The use of viruses to kill tumor cells based on their increa...
Autores principales: | Cripe, Timothy P, Chen, Chun-Yu, Denton, Nicholas L, Haworth, Kellie B, Hutzen, Brian, Leddon, Jennifer L, Streby, Keri A, Wang, Pin-Yi, Markert, James M, Waters, Alicia M, Gillespie, George Yancey, Beierle, Elizabeth A, Friedman, Gregory K |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4589755/ https://www.ncbi.nlm.nih.gov/pubmed/26436135 http://dx.doi.org/10.1038/mto.2015.15 |
Ejemplares similares
-
Pediatric cancer gone viral. Part II: potential clinical application of oncolytic herpes simplex virus-1 in children
por: Friedman, Gregory K, et al.
Publicado: (2015) -
Effect of Repeat Dosing of Engineered Oncolytic Herpes Simplex Virus on Preclinical Models of Rhabdomyosarcoma()
por: Waters, Alicia M., et al.
Publicado: (2016) -
Preclinical Evaluation of Engineered Oncolytic Herpes Simplex Virus for the Treatment of Neuroblastoma
por: Gillory, Lauren A., et al.
Publicado: (2013) -
Preclinical Evaluation of Engineered Oncolytic Herpes Simplex Virus for the Treatment of Pediatric Solid Tumors
por: Megison, Michael L., et al.
Publicado: (2014) -
Myelolytic Treatments Enhance Oncolytic Herpes Virotherapy in Models of Ewing Sarcoma by Modulating the Immune Microenvironment
por: Denton, Nicholas L., et al.
Publicado: (2018)